(Bloomberg) -- The New York City official in charge ofprotecting the city’s pension funds for teachers,firefighters, police and city employees wants Mylan NV to name anindependent chairman, saying the recent controversy over theprice of the EpiPen allergy shot is an example ofthe board’s failure to oversee risk.
“Mylan’s gross mismanagement of its EpiPen pricing strategyexacerbates the company’s protracted history of weak boardoversight,” New York City Comptroller Scott Stringer said in aletter Thursday to Mylan director Douglas Leech, who chairs thenominating and governance committee.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
